In an open‐label Phase Ib trial, gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate (ORR) with acceptable safety in women with hormone receptor‐positive, HER2(−) advanced breast cancer [163]. This evidence concerns the gene NR4A1 and breast carcinoma.